IP Library Granted Patent US 8,372,422
Granted Patent B2
US 8,372,422 · App. 12/899,521 · Granted Feb 12, 2013

Hydroxyapatite-targeting poly(ethylene glycol) and related polymers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,372,422
App. No.
12/899,521
Granted
Feb 12, 2013
Kind
B2
Abstract

Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.

Claims (19)

1. A method for attaching a hydroxyapatite-targeting water-soluble polymer to a surface or device, said method comprising the steps of:

a) providing a water-soluble polymer comprising at one terminus, a hydroxyapatite-targeting moiety, and

b) binding the water-soluble polymer from step (a) with a hydroxyapatite- or calcium phosphate-coated prosthetic or drug delivery device or surface under conditions effective to promote said binding.

2. The method of claim 1 , wherein the water-soluble polymer is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrolidone), poly(hydroxypropylmethacrylamide), poly(α-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, and copolymers and terpolymers thereof.

3. The method of claim 2 , wherein the water-soluble polymer is a poly(alkylene glycol).

4. The method of claim 3 , wherein the water-soluble polymer is a poly(ethylene glycol).

5. The method of claim 4 , wherein the poly(ethylene glycol) is linear.

6. The method of claim 4 , wherein the poly(ethylene glycol) is branched.

7. The method of claim 4 , wherein the water-soluble polymer has a molecular weight ranging from about 100 daltons to about 100,000 daltons.

8. The method of claim 7 , wherein the water-soluble polymer has a molecular weight ranging from about 6,000 daltons to about 80,000 daltons.

9. The method of claim 1 , wherein the hydroxyapatite-targeting moiety is selected from the group consisting of tetracycline, calcein, bisphosphonates, polyaspartic acid, polyglutamic acid, and aminophosphosugars.

10. The method of claim 1 , wherein the hydroxyapatite-targeting moiety is a bisphosphonate.

11. The method of claim 10 , wherein the bisphosphonate is selected from the group consisting of etidronate, alendronate, and 3-amino-1-hydroxypropane-1-1-diphosphonic acid (AHPDP).

12. The method of claim 10 , wherein the water-soluble polymer is a poly(ethylene glycol).

13. The method of claim 1 , wherein the water-soluble polymer comprises at a second terminus, a biologically active agent.

14. The method of claim 1 , wherein the water-soluble polymer comprises at a second terminus, a protecting group.

15. The method of claim 14 , wherein the protecting group is protected hydroxyl.

16. The method of claim 1 , wherein said binding comprises incubating the hydroxyapatite or calcium phosphate coated prosthetic or drug delivery device or surface with a solution comprising the hydroxyapatite-targeting water-soluble polymer under conditions effective to promote binding thereto.

17. A hydroxyapatite- or calcium phosphate-coated prosthetic or drug delivery device or surface comprising a water-soluble polymer having at one terminus, a hydroxyapatite-targeting moiety, bound thereto.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →